Edwards Laboratories

Edwards Lifesciences, originally founded as Edwards Laboratories in 1958, is a global leader in medical innovations for structural heart disease and critical care monitoring. The company is best known for pioneering the first commercially viable artificial heart valve and remains a dominant force in the transcatheter aortic valve replacement (TAVR) market with its SAPIEN valve series. Beyond heart valves, Edwards provides advanced hemodynamic monitoring technologies used in surgical and intensive care settings to improve patient outcomes. Headquartered in Irvine, California, the company operates globally, focusing on minimally invasive therapies for heart valve repair and replacement. Its robust pipeline includes next-generation transcatheter mitral and tricuspid therapies (TMTT) designed to treat a broader range of patients.